Objectives: The purpose of this study was to evaluate the 5-year follow-up (FU) data of the
THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal …

Background—The success of percutaneous intervention in peripheral arterial disease is
limited by restenosis. The aim of the present pilot study was to evaluate a novel method of …

Background—Randomized controlled trials have reported favorable 1-year outcomes with
drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease …

Background: Evidence from large, randomized, controlled peripheral artery disease trials
reporting long-term outcomes using drug-coated balloons (DCBs) is limited. Previously, the …

Objectives This study sought to evaluate the safety and effectiveness of the Ranger drug-
coated balloon (DCB)(paclitaxel dose density 2 μg/mm2) for treating superficial femoral …

Objectives: This study sought to evaluate the safety and efficacy of the Lutonix drug-coated
balloon (DCB) coated with 2 μg/mm2 paclitaxel and a polysorbate/sorbitol carrier for …

Objectives: The aim of this study was to investigate the efficacy and safety of a new
paclitaxel-coated balloon catheter in the treatment of stenotic or occluded femoropopliteal …

Objectives: The authors sought to evaluate the performance of the Ranger paclitaxel-coated
balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months …

Background—Peripheral percutaneous transluminal angioplasty is fraught with a substantial
risk of restenosis and reintervention. A drug-eluting balloon (DEB) based on a novel coating …

Objectives: The aim of this study was to appraise 1-year outcomes after percutaneous
treatment of long femoropopliteal artery disease using paclitaxel-coated balloons …